Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcin.2015.10.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Off-Label Use of Balloon-Expandable Transcatheter Valves to Treat Pure Aortic Regurgitation.
Am J Cardiol
July 2024
Cardiology Unit, IRCCS University Hospital of Bologna, Policlinico S. Orsola, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy. Electronic address:
Transcatheter aortic valve implantation (TAVI) in native pure aortic regurgitation (AR) with off-label use of balloon-expandable valves (BEV) has been reported. However, there are scant data regarding optimal oversizing and its safety, and our study assessed BEV oversizing and outcomes of TAVI. Thirteen consecutive tricuspid aortic valve patients who underwent transfemoral TAVIs for pure AR with Sapien BEV at our center between 2019 and 2023 (69.
View Article and Find Full Text PDFRedo Transcatheter Aortic Valve Implantation in the Lotus Mechanically Expanded Transcatheter Heart Valve: Bench-Top Analysis, Clinical Experience, and Procedural Guidance.
Circ Cardiovasc Interv
November 2023
Department of Cardiology, Leeds General Infirmary, United Kingdom (M.A., D.J., D.J.B.).
Background: Redo transcatheter aortic valve implantation (TAVI) is increasing as patients outlive their transcatheter heart valves (THVs) and present with bioprosthetic valve failure. The Lotus mechanically expanded THV has unique design characteristics, which have specific implications for Redo TAVI.
Methods: The design features of the Lotus valve and their relevance to Redo TAVI were reviewed.
Performance of the 32 mm Myval transcatheter heart valve for treatment of aortic stenosis in patients with extremely large aortic annuli in real-world scenario: First global, multicenter experience.
Catheter Cardiovasc Interv
December 2023
University of Regensburg Medical Center, Regensburg, Germany.
Background: Extremely large aortic valve anatomy is one of the remaining limitations leading to exclusion of patients for transcatheter aortic valve replacement (TAVR).
Aims: The newly approved Myval 32 mm device is designed for use in aortic annulus areas up to 840 mm . Here we want to share the initial worldwide experience with the device.
Redo-TAVI with SAPIEN 3 in SAPIEN XT or SAPIEN 3 - impact of pre- and post-dilatation on final THV expansion.
EuroIntervention
November 2023
Centre for Cardiovascular Innovation, St Paul's Hospital, Vancouver, BC, Canada and Vancouver General Hospital, Vancouver, BC, Canada.
Background: When a balloon-expandable transcatheter heart valve (THV) is chosen to treat a failed balloon-expandable THV, there is a risk of underexpansion with a potential impact on performance.
Aims: We aimed to assess the impact of pre- and post-dilatation on the expansion of balloon-expandable THVs after redo-transcatheter aortic valve implantation (TAVI).
Methods: Redo-TAVI was performed on the bench with a 23 mm SAPIEN 3 (S3) implanted within a 23 mm SAPIEN XT (SXT) or a 23 mm S3, both of which served as the "failed" THVs.
Long-Term Durability of Transcatheter Heart Valves: Insights From Bench Testing to 25 Years.
JACC Cardiovasc Interv
January 2020
Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, Canada. Electronic address:
Objectives: This study assessed the long-term durability of nominally deployed transcatheter heart valves (THV) to 1 billion cycles (equivalent to 25 years) and non-nominal (overexpansion, underexpansion, and elliptical) THV deployments to 200 million cycles (equivalent to 5 years) with accelerated wear testing.
Background: The long-term durability of THVs is currently unknown. As transcatheter aortic valve replacement expands to lower-risk patients, durability will be of increasing importance.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!